Screener Summaries Updates Institutions Sign In More Updates › Other Events › NSRX Other Events · Jun 9, 2026
On June 9, 2026, Nasus Pharma Ltd. announced positive results from a preclinical pharmacokinetic and safety study of… NSRX Nasus Pharma Ltd
On June 9, 2026, Nasus Pharma Ltd. announced positive results from a preclinical pharmacokinetic and safety study of its intranasal Ondansetron (NS003). The company also released an updated corporate presentation on its website. Nasus Pharma is a pharmaceutical company that develops intranasal drug delivery technologies.
More from Nasus Pharma Ltd Shareholders reject Proposal No. 4 at Nasus Pharma Annual and Special General Meeting Oct 8, 2026 Nasus Pharma enters ATM agreement with BTIG to sell shares for clinical development of NS002 Sep 18, 2026 On September 14, 2026, Nasus Pharma Ltd. announced that the U.S. Food and Drug Administration cleared its… Sep 14, 2026 Nasus Pharma Ltd. announced the resignation of Chief Financial Officer Eyal Rubin, effective September 18, 2026, to… Aug 19, 2026 Nasus Pharma Ltd. reported a net loss of $5.9 million for the six months ended June 30, 2026, compared to a $1.3… Aug 17, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
